ペプチド リーム。 創薬に新たな道を拓いたペプチド探索システム

ペプチドリーム (4587) : 株価/予想・目標株価 [PeptiDream]

😜The Company emphasizes the importance of ongoing dialogue with relevant stakeholders as well as understanding human rights implications relevant to its business activities from the perspectives of the people affected. Due to their small size, they can be taken orally and normally readily diffuse throughout the body and into cells, therefore are ideal for targeting intracellular targets. Dialogue with stakeholders PeptiDream considers that its initiatives to respect human rights should be developed continuously. They are ideal for extracellular targets although there is growing evidence that they can be used against intracellular targets also , are highly selective and effective, relatively safe and well tolerated, and can administered via a number of routes. In addition to cyclization technologies, PDPS also incorporates a variety of modification technologies, that allow for a variety of applications, of all of which significantly speed the drug discovery process. Supplier Code of Conduct PeptiDream is committed to understanding legal compliance, human rights, environmental conservation, and health and safety, associated with our supply chain. We request our suppliers to comply with this Supplier Code of Conduct in order to strengthen mutual trust and build sustainable business partnership. Constrained peptides are more rigid, which provides for greater affinity and selectivity and also for superior in vivo stability. This policy on respecting human rights is based on the International Bill of Human Rights, and the International Labor Organization ILO Declaration on Fundamental Principles and Rights in Labor, and the Guiding Principles on Business and Human Rights, and other international norms. However, recently it has become more and more difficult to identify and develop novel small molecule drugs that target the next generation of biological targets to treat disease. Our constrained peptides are ideally suited for this role, and exhibit significant advantages over other alternatives specifically over antibodies. PDTS Peptide Discovery Translation System is a cell-free completely reconstituted in vitro transcription-translation system that allows for the template-directed ribosomal synthesis of peptides. Also the method has been optimized to work with the proceeding PeptiDream technologies. To achieve this objective, we will take on challenges with full force under the following four elements of our corporate philosophy. Using the PDPS technology and modern drug discovery techniques, it is now increasingly possible to turn a peptide hit into a small molecule drug that can be just as effective as the original peptide hit but with all of the positive attributes of small molecules, and this is mainly due to the fact that PDPS uncovers starting points not found by current classic small molecule high-throughput screening HTS methods. Philosophy At PeptiDream, we aim to complete the development of therapeutics using non-standard peptides by applying our proprietary Peptide Discovery Platform System PDPS so as to meet unmet medical needs medical needs for which there is not yet an effective treatment method and assist people suffering from illness all over the world. PetiDream protects the welfare of children and does not accept the employment of children excluded if legally permitted. There are also significant advantages over current biologic therapeutics, in both easier quality control and less expensive manufacturing costs, both of which are extremely important toward reducing drug prices and controlling quality of future medicines. PD Display was developed at PeptiDream, and while it is conceptually similar to previous in vitro display methodologies, it is extremely simplified and significantly faster than past methods. To ensure PeptiDream meets these social standards and norms, and to promote procurement activities considering them, we articulated this Supplier Code of Conduct. Through continuing these efforts and disclosing relevant information, we will continue to improve our human rights activities. This technological achievement allows PeptiDream to produce peptide libraries of almost limitless chemical diversity trillions in a single tube for one library, and trillions of library combinations possible unrivaled by any other hit finding technology. The cargos that can be conjugated to these homing peptides is virtually unlimited, from cell-killing toxins, small molecule drugs that need to be targeted, nanoparticle containing drugs, siRNA drugs, and other immunomodulatory and immune stimulatory compounds. By applying our proprietary Peptide Discovery Platform System PDPS , which is a world-leading technology, we contribute to creating the market for peptide drug discovery, the third market following those of low molecular drugs and antibody drugs, thereby contributing to advances in medicine around the world. These achievements contribute to the ability to screen identified hit candidates rapidly, compared to other technologies, and also to optimize hit candidates faster than was possible before. This allows for PeptiDream to identify hit candidates in a fraction of the time required by other technologies, and also for greater reproducibility and for virtually no person-to-person variability.。

11

ペプチドリーム株式会社|投資先企業|UTEC

💅。

20
。 。

ペプチドリーム株式会社とPDPS(ペプチド創薬プラットフォームシステム)に関する ライセンス契約を締結

💋。

「ペプチドリーム」のニュース一覧: 日本経済新聞

😚。 。 。

15

「ペプチドリーム」のニュース一覧: 日本経済新聞

✊。 。

。 。

STORY01 Pepti Dream×UTEC 奇跡の薬をつくる。ペプチドリームの挑戦。|UTEC

🙄。 。 。

。 。

ペプチドリーム(ペプドリ)【4587】の大株主と資本異動情報|株探(かぶたん)

😘。

18

「ペプチドリーム」のニュース一覧: 日本経済新聞

♻。 。 。

6

ペプチドリーム株式会社とPDPS(ペプチド創薬プラットフォームシステム)に関する ライセンス契約を締結

🙄。 。 。

3
。 。